US biopharmaceutical finance and the sustainability of the biotech business model

Research Policy

Volumn 40, Issue 9, 2011, Pages 1170-1187

  Lazonick, William ^a,b   Tulum, Öner ^b  

^a UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

^b Academic Industry Research Network (TheAIRnet)   (United States)

Author keywords

Corporate governance; Orphan drug; R D finance; Shareholder value; Stock repurchase; US biopharmaceutical innovation

Indexed keywords

CORPORATE GOVERNANCE; ORPHAN DRUG; SHAREHOLDER VALUES; STOCK REPURCHASE; US BIOPHARMACEUTICAL INNOVATION;

DRUG PRODUCTS; ECONOMICS; INDUSTRY; INVESTMENTS; KNOWLEDGE BASED SYSTEMS; PROFITABILITY; SHAREHOLDERS; SUSTAINABLE DEVELOPMENT;

BIOTECHNOLOGY;

EID: 80053988214     PISSN: 00487333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.respol.2011.05.021     Document Type: Article

References (91)

1. D. Aboody, and B. Lev Information asymmetry, R&D, and insider gains The Journal of Finance 25 2000 2747 2766
2. C.P. Adams, and V.V. Brantner Estimating the cost of new drug development: is it really $802 Million? Health Affairs - MarketWatch 25 2006 420 428 (Pubitemid 43529550)
3. R.G. Adler Biotechnology as an intellectual property Science 224 1984 357 363 (Pubitemid 14133994)
4. A. Arora, and A. Gambardella The changing technology of technological change: general and abstract knowledge and the division of innovative labour Research Policy 23 1994 523 532
5. D. Audretsch Standing on the shoulders of midgets: the U.S small business innovation research program (SBIR) Small Business Economics 20 2003 129 135
6. V. Bastin, and G. Hubner Concentrated announcements on clustered data: an event study on biotechnology stocks Financial Management 35 2006 129 157 (Pubitemid 43935977)
7. Burrill, G.S.; 2005. Biotech 2005 Industry Review & Outlook. Burrill & Company, presentation to BioPartnering North America, February 7, available at http://www.burrillandco.com/pdfs/BioPartnering-N-America.pdf.
8. Caremark, 2006. Trends Rx Report (downloaded from http://www.caremark. com/portal/asset/2006-TrendsRxReport.pdf).
9. Centers for Medicare and Medicaid (CMS), 2007. US Department of Health and Human Services. Office of Public Affairs, 2007. Medicare drug plans strong and growing, January 30, (downloaded from http://www.cms.hhs.gov/ PrescriptionDrugCovGenIn/02-EnrollmentData.asp).
10. M. Chase Amgen cuts mark biotech squeeze Wall Street Journal 2007 August 16 (downloaded from http://online.wsj.com/article/SB118720529438898746.html)
11. I.M. Cockburn, and S. Stern Finding the endless frontier: lessons from the life sciences innovation system for technology policy Capitalism and Society 5 2010 (1), article
12. B. Coriat, and F. Orsi Establishing a new intellectual property rights regime in the United States; origins contents, and problems Research Policy 31 2002 1491 1507
13. J. Cortright, and H. Mayer Signs of Life: The Growth of Biotechnology Centers in the US 2002 The Brookings Institution Center on Urban and Metropolitan Policy
14. J.A. DiMasi, and H.G. Grabowski The cost of biopharmaceutical R&D: is biotech different? Managerial and Decision Economics 28 2007 469 479
15. J.A. DiMasi, R.W. Hansen, and H.G. Grabowski The price of innovation: new estimates of drug development costs Journal of Health Economics 22 2003 151 185 (Pubitemid 36279392)
16. J.A. DiMasi, R.W. Hansen, and H.G. Grabowski Extraordinary claims require extraordinary evidence Journal of Health Economics 24 2005 1034 1044
17. J.A. DiMasi, R.W. Hansen, and H.G. Grabowski Setting the record straight on setting the record straight: response to the light and Warburton Rejoinder Journal of Health Economics 24 2005 1049 1053
18. R.S. Eisenberg Genes, patents, and product development Science 257 1992 903 908
19. R.S. Eisenberg How can you patent genes? American Journal of Bioethics 2 2002 3 10
20. Ernst & Young Beyond Borders: Global Biotechnology Report 2009 2009 EYGM Limited
21. S. Fazeli The European biotech sector: could it achieve more? Journal of Commercial Biotechnology 12 2005 10 19 (Pubitemid 43009288)
22. M.P. Feldman The locational dynamics of the US biotech industry: knowledge externalities and the anchor hypothesis Industry and Innovation 10 2003 311 328
23. Food and Drug Administration (US Department of Health and Human Services), 2009. List of Orphan Drug Designations and Approvals. Updated May 5, 2009, downloaded from (http://www.fda.gov/downloads/ForIndustry/ DevelopingProductsforRareDiseasesConditions/ HowtoapplyforOrphanProductDesignation/UCM162066.xls).
24. M. Fortun Mediated speculations in the genomics future markets New Genetics and Society 20 2001 139 156 (Pubitemid 32783428)
25. L. Galambos Innovation and industry evolution: a comment M. Mazzucato, G. Dosi, Knowledge Accumulation and Industry Evolution: The Case of Pharma-Biotech 2006 Cambridge University Press Cambridge 145 160
26. L. Galambos, and J.L. Sturchio Pharmaceutical firms and the transition to biotechnology: a study in strategic innovation Business History Review 72 1998 250 278
27. S.A. Garcia Patenting DNA: who defines and protects the public good? American Journal of Bioethics 2 2002 25 26
28. A. Gibbons Orphan drug compromise Bush-Whacked Science Magazine 250 1990 905
29. Gillis, J.; 1998. Biotech's Payday Arrives: After Costly, Uncertain Start, More Firms are Turning a Profit. Washington Post, July 5.
30. H.G. Grabowski, J. Vernon, and J.A. DiMasi Returns on research and development for 1990s new drug introductions Pharmacoeconomics 20 Suppl. 3 2002 11 29 (Pubitemid 35397395)
31. Griffith, V.; 2002. Novartis moves global research HQ to Boston. Financial Times, May 5.
32. B.J. Hall, and J.B. Leibman Are CEOs really paid like bureaucrats? Quarterly Journal of Economics 113 1998 653 691
33. D.A. Harris The impact of hot issue markets and noise traders on stock exchange listing standards University of Toronto Law Journal 56 2006 223 280
34. H.E. Heemstra, R.L. de Vrueh, S. van Weely, H.A. Büller, and H.G. Leufkens Predictors of orphan drug approval in European Union European Journal of Clinical Pharmacology 64 2008 545 552
35. M.A. Heller, and R.S. Eisenberg Can patents deter innovation? The anticommons in biomedical research Science 280 1998 698 701 (Pubitemid 28243336)
36. Hess, J.; Evangelista, E.; 2003. Pharma-biotech alliances: jockeying for position in the race to become "partner of choice". Contract Pharma, September.
37. J.M. Hogan Revamping the orphan drug act: potential impact on the world pharmaceutical market Law and Policy in International Business 26 1995 523 561
38. G. Huberman, and T. Regev Contagious speculation and a cure for cancer: a nonevent that made stock prices soar The Journal of Finance 26 2001 387 396
39. A.B. Jaffe, and J. Lerner Reinventing public R&D: patent policy and the commercialization of national laboratory technologies RAND Journal of Economics 32 2001 167 198
40. M.C. Jensen, K.J. Murphy, and E.G. Wruck CEO Pay... and How to Fix It. Harvard Business School NOM Working Paper No. 04-28 2005 Harvard Business School Boston (Downloaded from http://www.nber.org/∼confer/2005/si2005/cg/jensen. pdf
41. M. Kenney, and R. Florida Venture capital in silicon valley: fueling new firm formation M. Kenney, Understanding Silicon Valley: The Anatomy of an Entrepreneurial Region 2000 Stanford University Press California 98 123
42. D.J. Kevles Diamond vs. Chakrabarty and beyond: political economy of patenting life A. Thackray, Private Science: Biotechnology and the Rise of the Molecular Sciences 1998 University of Pennsylvania Press Philadelphia 65 79
43. Y. Ko An economic analysis of biotech patent protection The Yale Law Journal 102 1992 777 804
44. A. Kornberg The Golden Helix: Inside Biotech Ventures 1995 University Science Books California
45. W. Lazonick Innovative enterprise and historical transformation Enterprise & Society 3 2002 35 54
46. W. Lazonick The innovative firm J. Fagerberg, D. Mowery, R. Nelson, The Oxford Handbook of Innovation 2004 Oxford University Press Oxford 29 55
47. W. Lazonick Sustainable Prosperity in the New Economy? Business Organization and High-Tech Employment in the United States 2009 W.E. Upjohn Institute for Employment Research Michigan
48. W. Lazonick The new economy business model and the crisis of US capitalism Capitalism and Society 4 2 2009 article 4
49. W. Lazonick Innovative business models and varieties of capitalism: financialization of the US corporation Business History Review 84 2010 675 702
50. W. Lazonick The Chandlerian corporation and the theory of innovative enterprise Industrial and Corporate Change 19 2010 317 349
51. W. Lazonick The explosion of executive pay and the erosion of American prosperity Entreprises et Histoire 57 2010 141 164
52. Lazonick, W.; 2011. The Fragility of the US Economy: The Financialized Corporation and the Disappearance of the Middle Class Working Paper. The Academic-Industry Research Network, January.
53. Lazonick, W.; March, E.; Tulum, Ö.; 2007. Boston's Biotech Boom. Center for Industrial Competitiveness Working Paper. University of Massachusetts, Lowell, May 2007.
54. W. Lazonick, and M. O'Sullivan Maximizing shareholder value: a new ideology for corporate governance Economy and Society 29 2000 13 35 (Pubitemid 30172464)
55. W. Lazonick, and M.E. Sakin Do financial markets support innovation or inequity in the drug development process Paper Presented at the DIME Workshop, Innovation and Inequality: Pharma and Beyond Pisa, Italy, May 15 2010 (Available at http://www.innovation-equity.eu/file-upload/william-lazonick-mustafa-erdem- sakinc-paper.pdf
56. J. Lerner, H. Shane, and A. Tsai Do equity financing cycles matter? Evidence from biotechnology alliances Journal of Financial Economics 67 2003 411 446 (Pubitemid 36224036)
57. Lewin, T.; 1982. The patent race in gene-splicing. New York Times, August 29.
58. D.W. Light, and R.N. Warburton Extraordinary claims require extraordinary evidence Journal of Health Economics 24 2005 1030 1033
59. D.W. Light, and R.N. Warburton Setting the record straight in the reply by DiMasi, Hansen and Grabowski Journal of Health Economics 24 5 2005 1045 1048
60. Lorenzo, A.; 2006. Affymax completes $92M IPO. Bioworld Today, December 18.
61. G.S. McMillan, F. Narin, and D.L. Deeds An analysis of the critical role of public science in innovation: the case of biotechnology Research Policy 29 2000 1 8
62. P. McNamara, and C. Baden-Fuller Shareholder returns and the exploration-exploitation dilemma: R&D announcements by biotechnology firms Research Policy 36 2007 548 565 (Pubitemid 46679052)
63. R.P. Merges, and R.R. Nelson On the complex economics of patent scope Columbia Law Review 90 1990 839 916
64. A.S. Meyers History of the American Orphan Drug Act Speech at the International Conference of Rare Diseases and Orphan Drugs Spain, February 18 2000 (Downloaded from http://www.rarediseases.org/news/speeches/span2
65. Montgomery, L.; Lee, C.; 2006. Success of drug plan challenges democrats. Washington Post, November 26.
66. G. Moore VCs, angel investors: IPOs may be frozen until 2011 Mass High Tech 2008 December 18 (downloaded from http://thehartfordtechnologyincubator. com/Docs/MHT-VCs,%20angel%20investors-IPOs%20may%20be%20frozen%20until%202011- 121908.pdf)
67. D. Mowery, R. Nelson, B. Sampat, and A. Zledonis Ivory Tower and Industrial Innovation: University-Industry Technology Transfer Before and After the Bayh-Dole Act 2004 Stanford University Press California
68. Nakajima, E.; Loveland, R.; 2007. A Critical Alliance: The Biotechnology & Pharmaceutical Industries in Massachusetts. University of Massachusetts Donahue Institute Report Prepared for the Massachusetts High Technology Council, (downloaded from http://www.mhtc.org/UMass-Donahue-Institute-BioPharma-Report- 11April-FINAL.pdf).
69. National Center for Health Statistics (NCHS), 2006. Health, United States 2006. US Government Printing Office.
70. National Human Genome Research Institute (NHGRI) and Office of Rare Diseases (ORD) of the National Institutes of Health, 2005. US Department of Health and Human Services. 2005 Genetic and Rare Disorders, National Institutes of Health publication no, 05-5215, June, (downloaded from http://rarediseases. info.nih.gov/files/GARD-brochure-English.pdf).
71. National Institutes of Health, 2009. The NIH Almanac - Appropriations. (Downloaded from http://www.nih.gov/about/almanac/appropriations/index.htm).
72. National Research Council, 1997. Intellectual Property Rights and Research Tools in Molecular Biology. National Academy Press, (downloaded from http://www.sjbiocenter.com/grid/reference/MolecularBiologyIntellectualProperty. pdf).
73. L. Orsenigo, G. Dosi, and M. Mazzucato The dynamics of knowledge accumulation, regulation, and appropriability in the pharma-biotech sector: policy issues M. Mazzucato, G. Dosi, Knowledge Accumulation and Industry Evolution 2006 Cambridge University Press Cambridge 402 431
74. O'Sullivan, J.; 2008. Medicare Plan D. Prescription Drug Benefit: A Primer. CRS Report to Congress, March 18. (Downloaded from http://aging.senate. gov/crs/medicare12.pdf).
75. J. Owen-Smith, and W.W. Powell Knowledge networks as channels and conduits: the effects of spillovers in the Boston biotechnology community Organization Science 15 2004 5 21 (Pubitemid 38390323)
76. Phil-Carey, K.; 2006. Affymax partners anemia drug in Japan for $102m. Bioworld Today, February 14.
77. G.P. Pisano Can science be a business? Lessons from biotech Harvard Business Review 84 10 2006 114 125
78. P. Pisano Gary Science Business: The Promise, The Reality, and The Future of Biotech 2006 Harvard Business School Press
79. K. Porter, K.J. Whittington, and W.W. Powell The institutional embeddedness of high-tech regions: relational foundations of the Boston biotechnology community S. Breschi, F. Malerba, Clusters, Networks, and Innovation 2006 Oxford University Press Oxford 261 299
80. Rosen, M.; 2006. 2006: a great biotech financing year, unless you were going public. Wisconsin Technology Network, December 18. (Downloaded from http://wistechnology.com/article.php?id=3565).
81. L. Schiff, and F. Murray Biotechnology financing dilemmas and the role of special purpose entities Nature Biotechnology 22 3 2004 271 277 (Pubitemid 38295757)
82. R.J. Shiller Irrational Exuberance 2000 Princeton University Press New Jersey
83. E. Silverman Who took the tech out of biotech? Nature Biotechnology 24 3 2006 255 256 (Pubitemid 43372139)
84. M.E. Solt SWORD financing of innovation in the biotechnology industry Financial Management 22 2 1993 173 187
85. D. Stern, and D. Reissman Specialty pharmacy cost management strategies of private health care payers Journal of Managed Care Pharmacy 12 2006 736 744 (Pubitemid 47398731)
86. Wakeman, S.; 2004. IP Portfolios and R&D Firm Commercialization Strategy: Evidence from Biotechnology Alliances (downloaded at http://elsa.berkeley.edu/∼bhhall/others/Wakeman04-IPPortfolios.pdf).
87. S. Wakeman A dynamic theory of technology commercialization strategy Paper to be Presented at the 25th DRUID Conference Copenhagen, Denmark, June 17-20 2008
88. J.P. Walsh, A. Arora, and W.M. Cohen The effects of research tool patents and licensing on biomedical innovation M. Mazzucato, G. Dosi, Knowledge Accumulation and Industry Evolution 2006 Cambridge University Press Cambridge
89. C.W. Wessner Venture Capital and the SBIR Program 2009 National Research Council
90. G. Wolff The Biotech Investor's Bible 2001 John Wiley & Sons New Jersey
91. Young, D.; 2007. U.S.; EU will use same orphan drug application. BioWorld Today, December 11.